IXHL

Incannex Healthcare Limited

There isn't enough reported data to score IXHL yet.

IXHL Fundamentals

MetricStatus
Unavailable
Under pressure
Unavailable
Unavailable

IXHL's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.

IXHL PE Valuation

IXHL has no meaningful PE right now: it lost money over the past year.

IXHL Forward outlook

There aren't enough analyst estimates for IXHL to show an outlook.

IXHL Risk to reward

ScenarioChangePrice
UpsideUnknownโ€”
DownsideUnknownโ€”

Calculated from the latest close: $2.02 on Nov 12.

There is not enough scenario data to assess IXHL's risk to reward.

IXHL Earnings Per Share

Q3 2024: $-42.21Q4 2024: $-42.21Q1 2025: $-36.81Q2 2025: $-40.50Q3 2025: $-32.40Q4 2025: $-23.10Q1 2026: $-17.45Q2 2026: $-1.75Q3 2026: $-1.30
Q3 2024: $-42.21Q4 2024: $-42.21Q1 2025: $-36.81Q2 2025: $-40.50Q3 2025: $-32.40Q4 2025: $-23.10Q1 2026: $-17.45Q2 2026: $-1.75Q3 2026: $-1.30
QuarterTTM EPSYoY
Q3 2026-$1.30+$31.10
Q2 2026-$1.75+$38.75
Q1 2026-$17.45+$19.36
Q4 2025-$23.10+$19.11
Q3 2025-$32.40+$9.81

IXHL is still losing money, but far less than before: $1.30 per share over the past year, against $42.21 at its worst in late 2024.

IXHL Quarterly Revenue

Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: $74,000Q4 2024: $12,000Q1 2025: $0Q2 2025: $0Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --Q3 2026: $0
Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: $74,000Q4 2024: $12,000Q1 2025: $0Q2 2025: $0Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --Q3 2026: $0

IXHL Free Cash Flow

Q4 2023: --Q1 2024: โˆ’$4MQ2 2024: โˆ’$4MQ3 2024: --Q4 2024: --Q1 2025: โˆ’$3MQ2 2025: โˆ’$1MQ3 2025: โˆ’$9MQ4 2025: โˆ’$5MQ1 2026: โˆ’$2MQ2 2026: $3MQ3 2026: $521,000
Q4 2023: --Q1 2024: โˆ’$4MQ2 2024: โˆ’$4MQ3 2024: --Q4 2024: --Q1 2025: โˆ’$3MQ2 2025: โˆ’$1MQ3 2025: โˆ’$9MQ4 2025: โˆ’$5MQ1 2026: โˆ’$2MQ2 2026: $3MQ3 2026: $521,000
QuarterFree cash flowYoY
Q3 2026$521K+$9.7M
Q2 2026$3.4M+$4.9M
Q1 2026-$2.5M+$698K
Q2 2025-$1.5M+$2.2M
Q1 2025-$3.2M+$1.2M

IXHL has burned cash in most quarters: โˆ’$3M over the past year, against โˆ’$17M the year before.

IXHL Total Shares

Q4 2023: 529,104Q1 2024: 529,104Q2 2024: 538,811Q3 2024: 588,094Q4 2024: 587,481Q1 2025: 654,418Q3 2025: 10MQ4 2025: 12MQ1 2026: 12MQ2 2026: 12MQ3 2026: 13M
Q4 2023: 529,104Q1 2024: 529,104Q2 2024: 538,811Q3 2024: 588,094Q4 2024: 587,481Q1 2025: 654,418Q3 2025: 10MQ4 2025: 12MQ1 2026: 12MQ2 2026: 12MQ3 2026: 13M
PeriodChange %Net change
Quarterly+7.6%+886K shares
1 year+21%+2.2M shares

IXHL has 13M diluted shares, up 21% from a year ago.

IXHL Net Leverage

IXHL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

IXHL Weekly Momentum

MetricValueStatus
RSI32.1Neutral
Stochastic3.0Oversold

IXHL's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).

IXHL PE vs Healthcare Sector

IXHL has no meaningful PE right now: it lost money over the past year.

IXHL Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$2.7326% below
20 week MA$3.1035% below
50 week MA$5.1661% below
100 week MA$13.685% below

IXHL is in a downtrend: it's below all four of its weekly moving averages, and 85% below its 100-week average.

IXHL Yearly ROI

YearStart priceEnd priceROI
2023$126.0$139.2+10%
2024$139.2$58.5-58%
2025$58.5$12.0-80%
2026 YTD$12.0$2.02-83%

IXHL has finished lower in two of the last three years. It's down 83% so far in 2026.

Give your agent the market.

Get API key